Related Experiment Video
Updated: Jun 19, 2026

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
Published on: June 18, 2014
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih-Min A Huang1, Yuji M Mishina, Shanming Liu
1Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.
Abstract:
The stability of the Wnt pathway transcription factor beta-catenin is tightly regulated by the multi-subunit destruction complex. Deregulated Wnt pathway activity has been implicated in many cancers, making this pathway an attractive target for anticancer therapies. However, the development of targeted Wnt pathway inhibitors has been hampered by the limited number of pathway components that are amenable to small molecule inhibition. Here, we used a chemical genetic screen to identify a small molecule, XAV939, which selectively inhibits beta-catenin-mediated transcription. XAV939 stimulates beta-catenin degradation by stabilizing axin, the concentration-limiting component of the destruction complex. Using a quantitative chemical proteomic approach, we discovered that XAV939 stabilizes axin by inhibiting the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. Thus, our study provides new mechanistic insights into the regulation of axin protein homeostasis and presents new avenues for targeted Wnt pathway therapies.
Insights
A new molecule, XAV939, targets cancer by stabilizing axin, a key protein in the Wnt pathway. This promotes the degradation of beta-catenin, inhibiting cancer growth and offering new therapeutic strategies.
Area of Science:
- Molecular Biology
- Cancer Biology
- Drug Discovery
Background:
- The Wnt pathway is crucial for cell development and is frequently dysregulated in cancers.
- Beta-catenin stability is tightly controlled by the destruction complex, making it a cancer target.
- Targeting the Wnt pathway is challenging due to limited druggable components.
Purpose of the Study:
- To identify small molecules that inhibit beta-catenin-mediated transcription.
- To elucidate the mechanism of action for novel Wnt pathway inhibitors.
Main Methods:
- Chemical genetic screen to identify XAV939.
- Quantitative chemical proteomics to identify XAV939 targets.
- Analysis of axin protein homeostasis and degradation pathways.
Main Results:
- XAV939 selectively inhibits beta-catenin transcription by stabilizing axin.
- XAV939 inhibits tankyrase 1 and tankyrase 2, enzymes that promote axin degradation.
- Tankyrase inhibition leads to increased axin levels and beta-catenin degradation via the ubiquitin-proteasome pathway.
Conclusions:
- XAV939 provides a novel therapeutic strategy by targeting axin stability.
- Inhibiting tankyrase offers a new approach for Wnt pathway-driven cancer therapy.
- Understanding axin regulation opens new avenues for cancer treatment.
Related Concept Videos
Destabilization of Microtubules
Canonical Wnt Signaling Pathway
Microtubule Instability
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway

